drugset / Trial / NCT00005841
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 1
Terminated
15 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.
Timeline
- Start
- 2000-06
- Primary completion
- 2000-12
- Completion
- 2002-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | progenipoietin | Unknown | 10 ug/kg | Subcutaneous |
| Subject | progenipoietin | Unknown | 20 ug/kg | Subcutaneous |
| Subject | progenipoietin | Unknown | 40 ug/kg | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |